← Back to Search

Fasting Mimicking Diet for Health Improvement

N/A
Waitlist Available
Led By Sara Espinoza, MD
Research Sponsored by L-Nutra Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 8
Awards & highlights

Study Summary

This trial will look at how fasting diet affects white blood cells in healthy people to see if it could help with health.

Who is the study for?
This trial is for generally healthy volunteers with a BMI between 20-35 who can consent to study procedures. It's not suitable for those on diabetes treatment (except metformin), with alcohol dependency, type 1 diabetes, pregnant women, immune suppression drug users, or anyone with conditions that the investigator feels are risky.Check my eligibility
What is being tested?
The study tests how a Fasting Mimicking Diet (FMD) affects autophagy in white blood cells over five days. Autophagy is the body's way of cleaning out damaged cells to regenerate newer, healthier cells.See study design
What are the potential side effects?
Potential side effects aren't detailed but may include hunger, fatigue, dizziness or irritability due to calorie restriction. Specific reactions could vary based on individual health and adherence to the diet.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Autophagy flux
Secondary outcome measures
Autophagy-related gene expression
Metabolomic change

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: FMD2-ProMeteExperimental Treatment1 Intervention
Subjects in FMD2 groups will be provided and asked to consume a 5-day low calorie fasting-mimicking diet (ProMeteTM).
Group II: FMD1-ProLonExperimental Treatment1 Intervention
Subjects in FMD1 groups will be provided and asked to consume a 5-day low calorie fasting-mimicking diet (ProLonTM).
Group III: ControlActive Control1 Intervention
Subjects in the control group will be asked to keep their normal diet during the study period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fasting Mimicking Diet
2021
N/A
~60

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioOTHER
452 Previous Clinical Trials
91,384 Total Patients Enrolled
L-Nutra IncLead Sponsor
7 Previous Clinical Trials
604 Total Patients Enrolled
Sara Espinoza, MDPrincipal InvestigatorThe University of Texas Health Science Center at San Antonio
2 Previous Clinical Trials
1,022 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment involve any participants who are 75 years of age or older?

"Based on the eligibility criteria, this clinical trial has a lower age limit of 25 and an upper boundary of 65."

Answered by AI

What demographics are allowed to participate in this clinical research?

"Qualified participants for this medical trial ought to adhere to a specific dietary protocol and be between the ages of 25 and 65. Approximately 30 persons are sought out in total."

Answered by AI

What is the current participation rate in this medical experiment?

"Affirmative. According to the information shared on clinicaltrials.gov, this research is presently recruiting participants at one location with an aim of enrolling 30 subjects. The trial was first published on May 2nd 2023 and its details were last updated on October 29th 2023."

Answered by AI

Are there vacancies for participation in this clinical trial?

"Yes, this clinical trial is open for enrollment. Initial postings were established on May 2nd 2023 and the most recent update was made to October 29th 2023 according to information available through clinicaltrials.gov"

Answered by AI
~0 spots leftby Apr 2024